Compare Abeona Therapeutics Inc (ABEO) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Nano Dimension Ltd - ADR — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Nano Dimension Ltd - ADR trades at $1.46 (market cap $307.34M). The key difference: Abeona Therapeutics Inc is the larger of the two by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| ABEO | NNDM | |
|---|---|---|
Market Cap | $373.32M | $307.34M |
Sector | Health | Technology |
52-Week High | $7.23 | $2.14 |
52-Week Low | $4.17 | $1.21 |
Enterprise Value | $228.22M | -$102.00M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Nano Dimension (NNDM) trades at $1.46, up 0.69% on the day, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue of $102.44M but a net loss of $293.30M, with negative cash flow from operations of $101.28M. Recent news highlights a proposed business combination with Infinite Epigenetics and ongoing shareholder disputes with Murchinson Ltd., reflecting strategic shifts and internal tensions.
Outlook remains challenged by persistent losses and cash burn, though the low P/B of 0.63 may attract value investors. Key risks include execution of the strategic plan, shareholder approval of the Infinite Epigenetics deal, and achieving profitability. Opportunities lie in cost reductions and potential synergies from mergers, but the stock faces significant fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
